Online citations, reference lists, and bibliographies.

18F-FDG Metabolic Tumor Volume And Total Glycolytic Activity Of Oral Cavity And Oropharyngeal Squamous Cell Cancer: Adding Value To Clinical Staging

Elizabeth H Dibble, Ana C. Lara Alvarez, Minh-Tam Truong, Gustavo A. Mercier, E. Francis Cook, Rathan Subramaniam
Published 2012 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
18F-FDG metabolic tumor volume (MTV) and total glycolytic activity (TGA) have been proposed as potential prognostic imaging markers for patient outcome in human solid tumors. The purpose of this study was to establish whether MTV and TGA add prognostic information to clinical staging in patients with oral and oropharyngeal squamous cell carcinomas (SCCs). Methods: The Institutional Review Board approved this Health Insurance Portability and Accountability Act–compliant single-institution retrospective study. Forty-five patients with histologically proven oral or oropharyngeal SCC underwent PET/CT for initial cancer staging and were included in the study. MTV was measured using a gradient-based method (PET Edge) and fixed-threshold methods at 38%, 50%, and 60% of maximum standardized uptake value (SUV). The TGA is defined as MTV × mean SUV. Bland–Altman analysis was used to establish the reliability of the methods of segmentation. Outcome endpoints were overall survival (OS) and progression-free survival. Cox proportional hazards univariate and multivariate regression analyses were performed. Results: In Cox regression models, MTV and TGA were the only factors significantly associated with survival outcome after adjusting for all other covariates including American Joint Committee on Cancer (AJCC) stage, with hazards ratio of 1.06 (95% confidence interval, 1.01–1.10; P = 0.006) and 1.00 (95% confidence interval, 1.00–1.01; P = 0.02). The model fit was significantly better when MTV was added to AJCC stage in model I (χ2 value change, 1.16–6.71; P = 0.01) and when TGA was added to AJCC stage in model II (χ2 value change, 1.16–4.37; P = 0.04). The median cutoff point of 7.7 mL for primary tumor MTV was predictive of time to OS (log rank P = 0.04). The median cutoff point of 55 g for PET Edge primary tumor TGA was predictive of time to OS (log rank P = 0.08), though the result was not statistically significant. Conclusion: Gradient-based segmentations of primary tumor MTV and TGA are potential 18F-FDG markers for time to survival in patients with oral and oropharyngeal SCC and may provide prognostic information in addition to AJCC stage. These exploratory imaging markers need validation in larger cohort studies.
This paper references
10.2967/jnumed.110.082370
PET and PET/CT of the Neck Lymph Nodes Improves Risk Prediction in Patients with Squamous Cell Carcinoma of the Oral Cavity
Chun-ta Liao (2011)
10.32388/ol2c8v
Social Security Death Index
Antonia Cellier (2010)
10.1007/s00259-010-1670-3
Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?
Reubendra Jeganathan (2010)
10.1016/j.ijrobp.2010.12.055
What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom.
Maria Werner-wasik (2012)
10.1007/s00259-006-0363-4
A gradient-based method for segmenting FDG-PET images: methodology and validation
Xavier Geets (2006)
10.3109/02841860903440270
Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy
Young Mi Seol (2010)
Available at: www.cancer.org/ Research/CancerFactsFigures/index
10.3174/ajnr.A1760
Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer
Rathan Subramaniam (2010)
10.1148/radiol.10091479
Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake.
Jessica M. Davison (2010)
10.1016/j.cllc.2011.05.001
Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
Percy P. Lee (2012)
10.1016/j.ijrobp.2003.12.039
Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose.
Abdelkarim Said Allal (2004)
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl (2009)
10.1016/j.radonc.2011.05.040
Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity.
James D Murphy (2011)
10.1007/s00259-011-1755-7
Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology
Mathieu Hatt (2011)
10.1080/02841860600815407
Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT
Gabriela Studer (2007)
10.1056/NEJMoa0912217
Human papillomavirus and survival of patients with oropharyngeal cancer.
K Kian Ang (2010)
diction of outcome in head - and - neck cancer patients using the standardized uptake value of 2 - [ 18 F ] fluoro - 2 - deoxy - D - glucose
AS Allal (2004)
Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
Andrew Quon (2007)
10.1210/jc.85.3.1107
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
Wenli Wang (2000)
Kaplan-Meier OS curves for PET Edge TGA # 55 g (solid red line) and TGA . 55 g
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
Ronald Boellaard (2004)
10.1016/j.oraloncology.2009.06.008
High 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma.
Christof Hofele (2009)
10.1007/s11307-010-0404-z
Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma—A Pilot Study Comparing Volumetric MRI and PET/CT
Xingchen Wu (2010)
Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.
Heikki Minn (1997)
10.1007/s00259-011-1789-x
Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study
Dominic A. X. Schinagl (2011)
10.1200/JCO.20.5.1398
Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy.
Abdelkarim Said Allal (2002)
10.2214/AJR.11.7172
Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.
David Hadiprodjo (2012)
Fluorodeoxyglucosepositron-emission tomography imaging of head and neck squamous cell cancer
RM Subramaniam (2010)
10.1016/j.oraloncology.2008.05.022
Staging and prognosis in head and neck cancer
M. van der Schroeff (2009)
10.1007/s00259-011-1838-5
Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer
Wei Huang (2011)
10.1016/j.oraloncology.2008.05.022
Staging and prognosis in head and neck cancer.
Marc P van der Schroeff (2009)
10.1016/j.ijrobp.2007.07.2333
Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
Dominic A. X. Schinagl (2007)
10.1016/j.ijrobp.2007.04.036
Metabolic tumor burden predicts for disease progression and death in lung cancer.
Percy P. Lee (2007)



This paper is referenced by
10.1186/s12885-019-5935-3
Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET
Guobing Liu (2019)
10.1016/j.bjorl.2019.10.014
Prognostic value of 18F-FDG PET/CT parameters and histopathologic variables in head and neck cancer.
Hale Aslan (2019)
10.1967/s002449910162
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
Víctor A Marín-Oyaga (2015)
10.3390/jcm9051390
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
Philipp E Hartrampf (2020)
10.3413/Nukmed-0749-15-06
A new method for segmentation of FDG PET metabolic tumour volume using the peritumoural halo layer and a 10-step colour scale. A study in patients with papillary thyroid carcinoma.
Sungmin Jun (2015)
10.1002/jso.25185
Prognostic value of 18F‐FDG PET/CT parameters in patients who undergo salvage treatments for recurrent squamous cell carcinoma of the larynx and hypopharynx
Jae Ryung Lee (2018)
10.2967/jnumed.112.109470
Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal
Jose G. Bazan (2013)
10.1111/1754-9485.12496
A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy
Myo Min (2017)
10.1007/s00259-014-2933-1
Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer
Nai-Ming Cheng (2014)
10.1016/j.ejrad.2019.108671
Prognostic value of 18F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma.
Chih-Wei Yu (2019)
10.1002/jso.24606
Discrepancy between cTNM and pTNM staging of oral cavity cancers and its prognostic significance
Nayeon Choi (2017)
10.1016/j.ejrad.2016.11.019
Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
Kazuhiro Kitajima (2017)
10.1245/s10434-014-3590-0
Metabolic Response to Preoperative Chemotherapy Predicts Prognosis for Patients Undergoing Surgical Resection of Colorectal Cancer Metastatic to the Liver
Lawrence F. Lau Mbbs (2014)
10.1186/s13014-019-1236-x
Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation
Yimin Li (2019)
10.1186/1748-717X-8-262
Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study
Malene Martini Clausen (2013)
10.1007/s12149-015-0994-2
High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma
Bo Hyun Kim (2015)
10.1117/1.JMI.4.1.011011
Practical no-gold-standard evaluation framework for quantitative imaging methods: application to lesion segmentation in positron emission tomography
Abhinav K. Jha (2017)
10.2217/IIM.13.73
FDG-PET/CT in the evaluation of paraneoplastic neurologic syndromes
Steven J. Sherry (2014)
10.2214/AJR.13.11673
PET/CT in the management of thyroid cancers.
Charles Marcus (2014)
10.2214/AJR.12.9653
Evolving role of FDG PET/CT in multiple myeloma imaging and management.
Ankit Agarwal (2013)
10.1007/s00455-018-9946-z
18F-FDG Metabolic Tumor Volume: Association with Short- and Long-Term Feeding Tube Use in Head and Neck IMRT
James E Jackson (2018)
10.2214/AJR.14.12497
Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma.
Krishna C Alluri (2014)
10.1002/cam4.119
Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer
Gary A Ulaner (2013)
10.1186/s12957-018-1441-3
Safflower polysaccharide inhibits the development of tongue squamous cell carcinoma
Haiyan Zhou (2018)
Prognostic correlation of the expression of glucose transporter with positron emission tomography in gallbladder cancer
김재근 (2016)
10.1097/RLU.0000000000000613
Prognostic Value of SUVmean in Oropharyngeal and Hypopharyngeal Cancers: Comparison with SUVmax and Other Volumetric Parameters of 18F-FDG PET
Kyoungjune Pak (2015)
10.1007/s00259-013-2625-2
FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity
Babak Saboury (2013)
10.1007/s12149-012-0604-5
Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy
Paul B Romesser (2012)
10.1016/j.ejrad.2015.07.033
Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings.
Kyung Won Lee (2015)
10.4103/bbrj.bbrj_75_18
Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan volumetric parameters in head-and-neck cancer patients after treatment
Mehrdad Bakhshyesh Karam (2018)
10.3747/co.26.4167
Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.
Maryam Dosani (2019)
10.21037/TCR.2020.03.16
Predicting response to radiotherapy in tumors with PET/CT: when and how?
Lifang Shen (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar